Brendan F Kohrn

No ORCID on file · 3 papers in corpus
observational 2024
Gynecologic Oncology ·doi:10.1016/j.ygyno.2024.07.690

BACKGROUND: Individuals with germline BRCA1 and BRCA2 pathogenic variants (BRCA carriers) are at high risk of developing high grade serous ovarian carcinoma (HGSC). HGSC is predominantly driven by TP53 mutations, but mutations in this gene …

lab-animal 2022
Cell & bioscience ·doi:10.1186/s13578-022-00852-0

BACKGROUND: More than 70% of leiomyomas (LM) harbor MED12 mutations, primarily in exon 2 at c.130-131(GG). The cause of MED12 mutations in myometrial cells remains largely unknown. We hypothesized that increased ROS promotes MED12 mutations…

other 2022
Cancer research communications ·doi:10.1158/2767-9764.crc-22-0314

Current screening methods for ovarian cancer (OC) have failed to demonstrate a significant reduction in mortality. Uterine lavage combined with TP53 ultra-deep sequencing for the detection of disseminated OC cells has emerged as a promising…